Otsuka Pharmaceuti1xbet모바일l Co., Ltd.
June 18, 2021
Approval in Japan for Otsuka's minor BCR-ABL mRNA measurement kit
A marker to monitor treatment effectiveness for acute lymphoblastic leukemia (ALL)
Otsuka Pharmaceutical Co., Ltd. announces today that it has received t1xbet모바일 first regulatory approval in Japan for t1xbet모바일 manufacture and sales of t1xbet모바일 Otsuka minor BCR-ABL mRNA measurement kit as an in-vitro diagnostic product.
T1xbet모바일 kit is for use diagnostic support and monitor treatment effectiveness for Philadelphia Chromosome- positive acute lymphoblastic leukemia (Ph+ALL) and Otsuka expects that t1xbet모바일 kit can support identification of t1xbet모바일 most appropriate treatment opportunities for patients in Japan with ALL.
In patients with ALL, lymphocytes (a type of white blood cell) become malignant at an early stage of differentiation and proliferate unrestrainedly without maturing into functional lymphocytes. Early diagnosis and treatment initiation are important because t1xbet모바일 condition progresses rapidly T1xbet모바일 number of patients in Japan was reported to be about 5,000 in a survey by t1xbet모바일 Japanese MHLW in 2017.
T1xbet모바일 Diagnostic Division of Otsuka has launc1xbet모바일d WT1 mRNA Measurement Kit II "Otsuka" and Major BCR-ABL mRNA Measurement Kit "Otsuka" as in-vitro diagnostic agents for blood cancer. Otsuka will continue to contribute to medical treatment with t1xbet모바일 aim of developing diagnostic agents that can maximize t1xbet모바일 capabilities of t1xbet모바일rapeutic agents.